CoChat
Sign Up
Cited by 140Diabetes Management and ResearchDiabetes and associated disordersDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

A novel diabetes typology: towards precision diabetology from pathogenesis to treatment

Open access
Herder, Christian, Roden, Michael·2022·Diabetologia
DOI 10.1007/s00125-021-05625-xPMC PMC9522691
Open this paper in CoChat — free accountOpen PDF

Abstract

The current classification of diabetes, based on hyperglycaemia, islet-directed antibodies and some insufficiently defined clinical features, does not reflect differences in aetiological mechanisms and in the clinical course of people with diabetes. This review discusses evidence from recent studies addressing the complexity of diabetes by proposing novel subgroups (subtypes) of diabetes. The most widely replicated and validated approach identified, in addition to severe autoimmune diabetes, four subgroups designated severe insulin-deficient diabetes, severe insulin-resistant diabetes, mild obesity-related diabetes and mild age-related diabetes subgroups. These subgroups display distinct patterns of clinical features, disease progression and onset of comorbidities and complications, with severe insulin-resistant diabetes showing the highest risk for cardiovascular, kidney and fatty liver diseases. While it has been suggested that people in these subgroups would benefit from stratified treatments, RCTs are required to assess the clinical utility of any reclassification effort. Several methodological and practical issues also need further study: the statistical approach used to define subgroups and derive recommendations for diabetes care; the stability of subgroups over time; the optimal dataset (e.g. phenotypic vs genotypic) for reclassification; the transethnic generalisability of findings; and the applicability in clinical routine care. Despite these open questions, the concept of a new classification of diabetes has already allowed researchers to gain more insight into the colourful picture of diabetes and has stimulated progress in this field so that precision diabetology may become reality in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-021-05625-x

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Possible future implications of precision diabetology based on the novel diabetes subgroups. Although the utility of the concept needs to be evaluated in RCTs, one may speculate on the potential implications of a new (sub)classification of diabetes for tailored diagnosis, prevention and treatment. Individuals in the different diabetes subgroups differ in their susceptibility to developing specific complications. The different (pathophysiological) phenotypes may also differ in their response to lifestyle-related and pharmacological strategies. SAID requires early introduction of insulin supplementation, whereas SIDD may also benefit from a dipeptidyl peptidase 4 inhibitor (DPP4i) or, when cost is a major issue, a sulfonylurea. SIRD and MOD would benefit from medication that induces weight loss (SGLT2i, GLP-1RA, dual agonist) or also addresses risk of CVD or nephropathy (SGLT2i, GLP-1RA). Providing that safety and efficacy have been established, new insulin sensitisers (e.g. peroxisome proliferator activator receptor agonists) or anti-inflammatory drugs could also improve targeted treatment of SIRD. On the other hand, individuals with MARD should receive treatments avoiding weight loss and sarcopenia (e.g. protein-balanced diets and moderate resistance training). PPARa, peroxisome proliferator activator receptor agonist. This figure is available as a downloadable slide
Fig. 1 Possible future implications of precision diabetology based on the novel diabetes subgroups. Although the utility of the concept needs to be evaluated in RCTs, one may speculate on the potential implications of a new (sub)classification of diabetes for tailored diagnosis, prevention and treatment. Individuals in the different diabetes subgroups differ in their susceptibility to developing specific complications. The different (pathophysiological) phenotypes may also differ in their response to lifestyle-related and pharmacological strategies. SAID requires early introduction of insulin supplementation, whereas SIDD may also benefit from a dipeptidyl peptidase 4 inhibitor (DPP4i) or, when cost is a major issue, a sulfonylurea. SIRD and MOD would benefit from medication that induces weight loss (SGLT2i, GLP-1RA, dual agonist) or also addresses risk of CVD or nephropathy (SGLT2i, GLP-1RA). Providing that safety and efficacy have been established, new insulin sensitisers (e.g. peroxisome proliferator activator receptor agonists) or anti-inflammatory drugs could also improve targeted treatment of SIRD. On the other hand, individuals with MARD should receive treatments avoiding weight loss and sarcopenia (e.g. protein-balanced diets and moderate resistance training). PPARa, peroxisome proliferator activator receptor agonist. This figure is available as a downloadable slideCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 1

  1. Mahajan A, Taliun D, Thurner M et al (2018) Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 50(11):1505–1513. https://doi.org/10.1038/s41588-018-0241-6 · DOI · Paper page

Cited by

Sorted by citations

Items 101–140 of 140

Related

See all

Metadata

Authors
Herder, C., & Roden, M.
Affiliations
Düsseldorf University Hospital (DE)
Corresponding author
  • Herder, Christian
  • Roden, Michael
ORCID
Venue
Diabetologia
Publisher
Springer Science and Business Media LLC
Published
2022-01-04
Volume
65
Issue
11
Pages
1770-1781
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
DOI
10.1007/s00125-021-05625-x
PMC
PMC9522691
OpenAlex
W4206342425
Cited by
140
References
69
Citations by year
2026: 21 · 2025: 37 · 2024: 34 · 2023: 33 · 2022: 15
FWCI
4.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
Funders
  • German Center for Diabetes Research
  • German Federal Ministry of Education and Research
  • German Federal Ministry of Health
  • Ministry of Culture and Science of the State of North Rhine-Westphalia
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
diabetes classification, diabetes subtypes, autoimmune diabetes, insulin-deficient diabetes, obesity-related diabetes, age-related diabetes, pathogenesis, diabetes complications, cardiovascular risk, diabetic nephropathy, hepatic steatosis, treatment stratification
MeSH terms
Diabetes Mellitus, Type 1, Humans, Hyperglycemia, Insulin Resistance, Comorbidity, Insulins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review